TIDMPXS
RNS Number : 5688C
Provexis PLC
29 June 2016
29 June 2016 Provexis plc
Product launch - Fruitflow(R) + Omega-3 dietary supplement
Provexis plc ("Provexis" or the "Company"), the business that
develops, licenses and sells the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is pleased to
confirm the launch of its new Fruitflow(R) + Omega-3 dietary
supplement product, which is exclusively available through the
Company's new e-commerce website www.fruitflowplus.com
Fruitflow(R) is a patented, scientifically-proven tomato extract
which inhibits platelet aggregation, a known cause of heart attack,
stroke and venous thrombosis. It is a natural product classified as
a food which is easy to digest.
In May 2009 Fruitflow(R) was the first technology to be
substantiated by the European Food Safety Authority ('EFSA') under
the new Article 13(5) for proprietary and emerging science. In
December 2009 the European Commission authorised the health claim
'Helps maintain normal platelet aggregation, which contributes to
healthy blood flow'.
In 8 human trials, consumption of Fruitflow(R) has been proven
to maintain healthy platelet aggregation and improve blood flow. In
the largest single study for Fruitflow(R), positive effects were
observed in 97% of individuals tested. This compares favourably
with single-drug therapies such as aspirin which can be ineffective
in up to 30% of individuals; further, there are no recorded side
effects from Fruitflow(R).
On 31 May 2016 the Company announced in a trading update that
more than 50 regional consumer healthcare brands containing
Fruitflow(R) have now been launched by direct customers of DSM,
with a number of further regional brands having been launched
through DSM's distributor channels.
Provexis seeks to harness the power of natural ingredients and
combine them with proven science to develop safe, clinically proven
cardioprotective solutions, hence the decision with this new
product to combine Fruitflow(R) with Omega-3 for even greater
cardioprotective effect.
Fruitflow(R)+ Omega-3 is a two-in-one supplement in an easy to
take capsule, supporting healthy blood flow and normal heart
function. The added ingredient of Omega-3 has a separate, positive
European Commission approved health claim: 'Omega-3 Fish Oil EPA
and DHA contribute to the normal function of the heart'.
Each Fruitflow(R)+ Omega-3 capsule contains 150mg of
Fruitflow(R), and 250mg of the purest Omega-3 to help boost DHA/EPA
levels. Taken daily, Omega-3 works by altering the balance of fats
that circulate in the blood, which are used for incorporation into
blood cells. A healthy balance of Omega-3/6 fats in blood cells is
reported to slow down formation of fatty plaques in the arteries,
helping to maintain normal heart function.
Fruitflow(R)+ Omega-3 offers the first 100% natural, safe,
scientifically proven solution for healthy blood flow and
cardiovascular health. It can be used in primary prevention for
healthy adults who understand the dangers of CVD and who want to
take control of their diet and lifestyle to maintain cardiovascular
health.
Initially the benefits of each Fruitflow(R)+ Omega-3 capsule
will last 12-18 hours, but with continued daily use the capsules
will provide 24 hour protection.
Fruitflow(R)+ Omega-3 marketing initiatives
The Company has been working on the marketing, public relations,
sales and fulfilment aspects of its new e-commerce channel with the
judicious use of expert outsourced partners and with continuing
support from DSM, and it has sought to minimise setup costs.
The Company is planning to conduct a Key Opinion Leaders
roundtable for Fruitflow(R) in September 2016, with considerable
support from DSM, which is expected to be a good opportunity to
promote Fruitflow(R) more widely across key digital and other
mainstream media channels.
The Company has setup a Facebook page for Fruitflow(R)+ Omega-3
- www.facebook.com/FruitflowPlus - and this will be updated on a
regular basis.
Fruitflow(R)+ Omega-3 will be promoted across DSM's key digital
communities and channels, to include boosted posts on DSM's
Facebook channels targeting health conscious consumers.
A digital marketing strategy has been agreed for the product,
seeking to drive and optimise online leads and sales and this will
be implemented in the coming weeks.
The Company is keen to increase the brand awareness and
potential sales of its Fruitflow(R)+ Omega-3 capsules, along with
the brand awareness of Fruitflow(R) more widely, and further sales
channel opportunities are under review.
The Company and DSM are keen to secure greater medical advocacy
for Fruitflow(R), particularly with reference to the US Food and
Drug Administration's guidance in May 2014 concerning the use of
low dose aspirin which remains a strong opportunity. Fruitflow(R)
has been promoted at some major cardiovascular health events,
including the European Society of Cardiology's annual congress in
London which was attended by more than 30,000 healthcare
professionals.
Marketing initiatives have also included DSM's product video for
Fruitflow(R) which is primarily targeted at potential business
customers for Fruitflow(R) in the consumer healthcare sector. The
video has been a good opportunity to promote Fruitflow(R) more
widely and it has been viewed by a wide variety of current and
prospective customers for Fruitflow(R). Further bespoke versions of
the video have been released, and a new promotional video has also
been shown to prospective customers in the US market. The product
video is available to view via the Company's websites
www.provexis.com and www.fruitflowplus.com
The Company remains in the process of submitting some of the
underlying scientific studies for Fruitflow(R) for publication in
appropriate scientific journals, to include the Company's Aspirin
Comparison Human Trial for Fruitflow(R) and a separate
'Fruitflow(R) review' paper. The Fruitflow(R) review paper includes
a scientific summary of the entire Fruitflow(R) project from its
inception. The publication of these two studies is expected to be a
significant opportunity to promote Fruitflow(R) further, with
further study publications envisaged in due course.
Fruitflow(R) and Blood Pressure - Collaboration with University
of Oslo
In November 2014 the Company signed a two stage collaboration
agreement with the University of Oslo to undertake further research
into the relationship between Fruitflow(R) and blood pressure
regulation. Recent work undertaken by the University has shown that
Fruitflow(R) has a potential new bioactivity, leading to blood
pressure lowering effects which would be of relevance to a large
number of consumers and patients with a wide range of
cardiovascular conditions.
The first stage of the collaboration work, completed in 2015,
was focussed on developing the science and the key results from
this stage were very encouraging, with strong evidence from the
laboratory based work that a standard 150mg dose of Fruitflow(R) in
powder format has the potential to give a clinically relevant
reduction in systolic blood pressure.
The Company and the University are now in the process of
conducting the second stage of the collaboration work which is
seeing the parties undertake a small clinical trial in Oslo by way
of a proof of principle study. Study designs were submitted for
ethics approval before finalisation, with a potential dosage for
the study of 150mg Fruitflow(R) in powder format twice per day. The
Company and the University expect to be able to complete the
clinical trial in the next few months and the results of the proof
of principle study will be announced as soon as possible
thereafter.
Dawson Buck, Chairman of Provexis, commented:
"We are delighted to announce the launch of our Fruitflow(R)+
Omega-3 dietary supplement product, a natural, safe, scientifically
proven solution for healthy blood flow and cardiovascular
health.
Fruitflow(R) and Omega-3 have separate, positive EFSA health
claims and the product packaging and related marketing programme
reflect these strongly.
The Company and DSM are committed to a number of ongoing
marketing initiatives for Fruitflow(R) and the Company's new
Fruitflow(R)+ Omega-3 capsules, seeking to give Fruitflow(R) and
this innovative new dietary supplement product further global
exposure.
The new Fruitflow(R)+ Omega-3 dietary supplement product is
expected to provide the Company with an additional income and
profit stream, and help to increase the brand awareness of
Fruitflow(R) more widely.
The product launch today is a very positive development for the
business, seeking to generate value for shareholders, and we remain
positive about the outlook for the product and the business."
-ends-
For further information please contact:
Provexis plc Tel: 07490 391888
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development and licensing
of its proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient.
In May 2009, the Company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ("EFSA")
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim "Helps maintain normal platelet aggregation, which
contributes to healthy blood flow", which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 50 regional consumer healthcare brands now having been
launched by direct customers of DSM, and with a number of further
regional brands having been launched through DSM's distributor
channels.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
On 29 June 2016 the Company launched a high quality dietary
supplement product containing Fruitflow(R) and Omega-3 which is
being sold initially from a separate, dedicated website
www.fruitflowplus.com on a mail order basis.
The Company is engaged in a two stage collaboration agreement
with the University of Oslo ('the University') to undertake further
research into the relationship between Fruitflow(R) and blood
pressure regulation. The Company is very pleased with the
encouraging results from the first stage of the collaboration with
strong evidence that a standard dose of Fruitflow(R) has the
potential to give a clinically relevant reduction in systolic blood
pressure. The Company and the University are now in the process of
conducting a small clinical trial by way of a proof of principle
study.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLDDGDLCGDBGLI
(END) Dow Jones Newswires
June 29, 2016 02:00 ET (06:00 GMT)
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2024 to May 2024
Provexis (LSE:PXS)
Historical Stock Chart
From May 2023 to May 2024